Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
In this educational workshop, Parexel regulatory experts, all former regulators, provide a comprehensive view of anti-drug conjugates (ADCs) for the treatment of cancer - from non-clinical, CMC, and clinical perspectives. In this 90-minute educational session, we explore how ADCs are developed and characterized in the non-clinical stage, the critical considerations, and challenges in manufacturing processes (CMC), and the exciting clinical developments shaping the landscape of cancer therapy. Join us as we delve into the multidimensional aspects of ADCs and their potential to revolutionize cancer treatment.
Related Insights
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
What Do the Next 10 Years Hold for CRISPR?
Jul 27, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Related Insights
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
What Do the Next 10 Years Hold for CRISPR?
Jul 27, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022